EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

NCT05059106 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

29637

Enrollment

OTHER

Sponsor class

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL: Half dose of ChAdOx1 nCoV-19 (AZD1222)
BIOLOGICAL: Standard dose of ChAdOx1 nCoV-19 (AZD1222)

Sponsor

Federal University of Espirito Santo

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]